Networks of Innovation: Vaccine Development at Merck, Sharp and Dohme, and Mulford, 1895-1995Networks of Innovation offers an historical perspective on the manner in which private-sector organizations have acquired, sustained, and periodically lost the ability to develop, manufacture, and market new serum antitoxins and vaccines. The primary focus is on the H. K. Mulford Company, on Sharp and Dohme, which acquired Mulford in 1929, and upon Merck & Co Inc., which merged with Sharp and Dohme in 1953. By surveying a century of innovation in biologicals, the authors are able to analyze the conditions that either promoted or prevented creative changes in this important industry. They show how the activities of these three commercial enterprises were related to a series of complex, evolving networks of scientific, governmental, and medical institutions in the United States and abroad. This is the first such history to draw exclusively on sources internal to Merck, one of the world's leading innovators in modern vaccines and pharmaceuticals. |
Contents
1894 The foremost medical question of the day | 1 |
The Mulford Story | 9 |
A Sharp Dohme Interlude | 33 |
The Virology Network and a New Program at Merck Sharp Dohme | 53 |
Hillemans Innovations First Phase | 79 |
Dangerous Interlude | 123 |
Transforming Bacteriology A Second Phase | 151 |
Other editions - View all
Networks of Innovation: Vaccine Development at Merck, Sharp & Dohme, and ... Louis Galambos,Jane Eliot Sewell No preview available - 1995 |
Common terms and phrases
A. A. McLean Adjuvant American Journal antibody antigen antitoxin bacteria biologicals Biology and Medicine Cell Biology clinical tests company's Control diphtheria doses Douglas E. B. Buynak England Journal epidemic Experimental Biology firm firm's globulin H. K. Mulford Company Hepatitis B Vaccine History Human Hepatitis immunization industry infection Infectious Disease Journal influenza vaccine innovation Institute JAMA Jeryl Lynn Journal of Medicine Journal of Public Lancet licensed Live Attenuated long cycle M. R. Hilleman Magic Shots Marek's Disease Max Tishler Merck & Co Merck Sharp MSDRL Mumps National Pediatrics percent pharmaceutical Philadelphia Pneumococcal Polysaccharide Vaccines pneumonia polio Poliomyelitis polysaccharide problems Public Health R. E. Weibel Roy Vagelos Rubella Vaccine Rubella Virus Vaccines scientific Scolnick serum Sharp & Dohme Society for Experimental Stokes strain tion United vaccine development Vagelos Viral virology Virus and Cell Viruses World Health Organization York ΜΑ